Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.56 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87013 | 0.91 | CHEK1 (0.52) | IRAK4TLR7CHEK1MAPK1ATM | |
| SCHEMBL86883 | 0.81 | ALDH1A1 (0.47) | NPC1RAB9AHDAC6HDAC2MAPT | |
| SCHEMBL82510 | 0.80 | HDAC1 (0.45) | NPC1RAB9AROCK2HDAC2MAPT | |
| Hydrochloric Acid SCHEMBL80801 | 0.79 | HDAC1 (0.44) | NPC1RAB9AROCK2HDAC2MAPT | |
| SCHEMBL86728 | 0.78 | L3MBTL1 (0.43) | TLR7NPC1RAB9AHDAC6HDAC2 | |
| SCHEMBL86754 | 0.77 | ALDH1A1 (0.48) | NPC1RAB9AATMMAPT | |
| SCHEMBL87019 | 0.74 | HTT (0.43) | NPC1RAB9AGAAMAPT | |
| SCHEMBL86615 | 0.74 | TYK2 (0.38) | ATMMAPT | |
| SCHEMBL86907 | 0.74 | KDM4E (0.41) | NPC1RAB9AMAPK1MAPT | |
| SCHEMBL87079 | 0.73 | CASP3 (0.41) | NPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| EP-2042504-B1 | Fused azole-pyrimidine derivatives | BAYER SCHERING PHARMA AG (DE) | 2011-06-01 | — | — | EP | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | IRAK4 81/4885TLR7 1604/4885CHEK1 317/4885 |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | KIT, CSNK2A1, CSNK1A1 | IRAK4 559/4885TLR7 269/4885CHEK1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.